<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557554</url>
  </required_header>
  <id_info>
    <org_study_id>IUSCC-0616 (1709077419)</org_study_id>
    <nct_id>NCT03557554</nct_id>
  </id_info>
  <brief_title>Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy</brief_title>
  <acronym>PIPN</acronym>
  <official_title>A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients With Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bryan Schneider</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massage Therapy Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility study to examine the preventative ability of massage therapy on paclitaxel
      induced peripheral neuropathy in breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    feasability and recruitment issues
  </why_stopped>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Actual">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">October 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Recruitment</measure>
    <time_frame>1 year</time_frame>
    <description>rate of enrollment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of Retention</measure>
    <time_frame>1 year</time_frame>
    <description>rate of drop out or consent withdraw</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of paclitaxel induced peripheral neuropathy</measure>
    <time_frame>10 months</time_frame>
    <description>incidence of paclitaxel induced peripheral neuropathy as measured using the Assessment of Cancer Therapy-Neurotoxicity (FACT-Ntx) questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of paclitaxel induced peripheral neuropathy</measure>
    <time_frame>10 months</time_frame>
    <description>severity of paclitaxel induced peripheral neuropathy measured by Assessment of Cancer Therapy-Neurotoxicity (FACT-Ntx) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pharmacological interventions</measure>
    <time_frame>10 months</time_frame>
    <description>pharmacological interventions for paclitaxel induced peripheral neuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paclitaxel dose modification</measure>
    <time_frame>4 months</time_frame>
    <description>rate of dose modifications to paclitaxel treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neuropathy</condition>
  <condition>Neuropathy;Peripheral</condition>
  <arm_group>
    <arm_group_label>Massage Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Massage</intervention_name>
    <description>A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.</description>
    <arm_group_label>Massage Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Breast cancer diagnosis 2) Planning to receive chemotherapy treatment with paclitaxel in
        the curative setting (adjuvant or neoadjuvant) on a weekly or bi-weekly schedule

        Exclusion Criteria:

        1)Diabetes or other neurological disorder 2) Current or previous peripheral neuropathy
        3)Previous treatment with paclitaxel 4)Active deep vein thrombosis (DVT) within last 12
        months or history of untreated lower extremity DVT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Bryan Schneider</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Massage</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

